Monday October 27, 2014 0 comments
FORT COLLINS - Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded $2 million by the U.S. Department of Defense to aid in the development and manufacture of a vaccine to protect against Ebola and other filoviruses.
The $2 million subcontract was awarded by Battelle Memorial Institute, a research organization that serves the DOD Medical Countermeasure System Joint Vaccine Acquisition Program.
Among the requirements of the award is to develop a vaccine to protect soldiers from aerosolized exposure to filoviruses that can cause several types of hemorrhagic fever, CSU said.
CSU said BioMARC will make contributions toward furthering the development of a replicon vaccine platform containing a non-infectious Ebola antigen, which has been shown to protect primates from an intramuscular and aerosol challenge with the Ebola virus.
To date, there are no licensed of FDA-approved human vaccines or therapeutics to protect against or treat filovirus infections.
"We welcome the opportunity to assist in a project that is of such great significance to protecting human health," said Dennis Pierro, BioMARC's director and a CSU professor.
"BioMARC was created to help with such projects."